104 related articles for article (PubMed ID: 21800006)
1. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Alessi MC; Nicaud V; Scroyen I; Lange C; Saut N; Fumeron F; Marre M; Lantieri O; Fontaine-Bisson B; Juhan-Vague I; Balkau B; Tregouet DA; Morange PE;
Thromb Haemost; 2011 Sep; 106(3):416-22. PubMed ID: 21800006
[TBL] [Abstract][Full Text] [Related]
2. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
3. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Appel SJ; Harrell JS; Davenport ML
J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
[TBL] [Abstract][Full Text] [Related]
4. Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease.
Aburto-Mejía E; Santiago-Germán D; Martínez-Marino M; María Eugenia Galván-Plata ; Almeida-Gutiérrez E; López-Alarcón M; Hernández-Juárez J; Alvarado-Moreno A; Leaños-Miranda A; Majluf-Cruz A; Isordia-Salas I
Biomed Res Int; 2017; 2017():6519704. PubMed ID: 28271069
[No Abstract] [Full Text] [Related]
5. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Glueck CJ; Sieve L; Zhu B; Wang P
Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878
[TBL] [Abstract][Full Text] [Related]
6. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
7. SNP276G>T polymorphism in the adiponectin gene is associated with metabolic syndrome in patients with type II diabetes mellitus in Korea.
Hwang JY; Park JE; Choi YJ; Huh KB; Kim WY
Eur J Clin Nutr; 2010 Jan; 64(1):105-7. PubMed ID: 19690575
[TBL] [Abstract][Full Text] [Related]
8. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study.
Ingelsson E; Pencina MJ; Tofler GH; Benjamin EJ; Lanier KJ; Jacques PF; Fox CS; Meigs JB; Levy D; Larson MG; Selhub J; D'Agostino RB; Wang TJ; Vasan RS
Circulation; 2007 Aug; 116(9):984-92. PubMed ID: 17698726
[TBL] [Abstract][Full Text] [Related]
9. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of metabolic syndrome among young women with nonfatal myocardial infarction.
Amowitz LL; Ridker PM; Rifai N; Loughrey CM; Komaroff AL
J Womens Health (Larchmt); 2004 Mar; 13(2):165-75; discussion 175. PubMed ID: 15072730
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome and the development of type 2 diabetes among professionals living in Beijing, China.
Zeng P; Zhu X; Zhang Y; Wang S; Zhang T
Diabetes Res Clin Pract; 2011 Nov; 94(2):299-304. PubMed ID: 21920619
[TBL] [Abstract][Full Text] [Related]
14. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
15. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
Festa A; Williams K; Tracy RP; Wagenknecht LE; Haffner SM
Circulation; 2006 Apr; 113(14):1753-9. PubMed ID: 16585388
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples.
von Känel R; Loredo JS; Ancoli-Israel S; Mills PJ; Dimsdale JE
Metabolism; 2007 Jul; 56(7):969-76. PubMed ID: 17570260
[TBL] [Abstract][Full Text] [Related]
17. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
18. Significance of vitronectin and PAI-1 activity levels in carotid artery disease: comparison of symptomatic and asymptomatic patients.
Ekmekçi H; Güngör Öztürk Z; Ekmekçi OB; Işler Bütün I; Beşirli K; Gode S; Atukeren P; Sönmez H
Minerva Med; 2013 Apr; 104(2):215-23. PubMed ID: 23514998
[TBL] [Abstract][Full Text] [Related]
19. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.
Martínez-Calatrava MJ; González-Sánchez JL; Zabena C; Martínez-Larrad MT; Luque-Otero M; Serrano-Ríos M
J Hypertens; 2007 Apr; 25(4):773-7. PubMed ID: 17351368
[TBL] [Abstract][Full Text] [Related]
20. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J
Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
